In human cancers, such as triple negative breast cancer (TNBC) and ovarian cancer, CD73 expression is generally associated with poor clinical outcomes, impaired tumor immune surveillance and resistance to chemotherapy (Loi et al., 2013; Bareche et al., 2021). This evidence concerns the gene NT5E and neoplasm.